title: Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report.
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA. Electronic address: rmckay5@partners.org.
authors.forename: Rana R
authors.initials: RR
authors.lastname: McKay
authors.affiliation: Tokai Pharmaceuticals, Inc, Cambridge, MA.
authors.forename: Khalid
authors.initials: K
authors.lastname: Mamlouk
authors.affiliation: University of Washington, Seattle, WA.
authors.forename: Bruce
authors.initials: B
authors.lastname: Montgomery
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Mary-Ellen
authors.initials: ME
authors.lastname: Taplin
mesh_terms: D000369:Aged, 80 and over; D000730:Androstadienes / Q000008:administration & dosage* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D015507:Drugs, Investigational; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000730:Androstadienes; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D015507:Drugs, Investigational; C500627:3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene
keywords: Androgen receptor; Androgen signaling; Anti-androgen; CYP17 inhibitor; Hormone therapy